Throughout the annals of human history, infectious diseases have occupied a central position, shaping societies, driving progress in medicine, and profoundly affecting the health of people globally. So, in the pursuit of noteworthy biological compounds, synthesis of a novel Schiff Base involved the condensation of 4- hydroxy benzaldehyde with octadecylamine, which subsequently interacted with the salts of Cu (II) and Ba (II) metals to generate their respective complexes.Different analytical methods, such as NMR (1H and 13C), IR, molar conductance, elemental analysis, and mass spectrometry, which indicates the complexes' tetrahedral stereochemistry via the N- and Cl-atoms of the ligands, were used to thoroughly characterize the compounds.Additionally, the bovine serum albumin (BSA) and serial dilution techniques were used to examine their therapeutic efficacy against bacterial, fungal, and inflammatory diseases. The protocols implemented demonstrated that the ligand's inhibitory characteristic was amplified upon complexation with a metal. The Ba-Schiff Base complex exhibits the greatest efficacy against bacterial and fungal pathogens, as evidenced by its antibacterial and antifungal activities. Its Minimum Inhibitory Concentration (MIC) values range from 0.0065 to 0.0141 μmol/mL, and it is found to be highly active against C. albicans, with a value of 0.0065 μmol/ML. BSA revealed that the Ba-Schiff Base complex demonstrates the lowest IC50 value of 07.25 ± 0.18 μM, signifying its superior efficacy for inflammatory conditions. The antibacterial, antifungal and antiinflammatory activities are well consistent with each other, stating the highest potency of Ba-Schiff Base complex for use as medicinal agent.